Therapeutic development & delivery
LL-37 looks like an ideal drug on paper and behaves like a difficult one in practice.
Why a promising peptide is so hard to turn into a drug
LL-37 looks like an ideal drug on paper and behaves like a difficult one in practice. Reviews of its development name the same four liabilities: high production costs, reduced efficacy under physiological conditions, susceptibility to proteolytic degradation, and significant toxicity to human cells. Turning it into a therapeutic means engineering around all four.
This unit surveys the obstacles and the strategies: shorter and modified analogs, nanoparticle and hydrogel delivery, fusion constructs, and where the whole pipeline actually stands. It is the practical bridge between LL-37 biology and any real-world use, and it is careful to say which of these have been tested in a person, which is one.